Kalaris Therapeutics names Liisa Bayko as CFO

KLRS•2026-07-20

Kalaris names new chief financial officer

Kalaris Therapeutics appointed Liisa Bayko as chief financial officer as it advances clinical development of TH103 for neovascular age-related macular degeneration.

Bayko previously served as managing director and senior biotechnology analyst at Evercore ISI, covering small- and mid-cap biotech companies.

Earlier roles included senior biotechnology analyst at JMP Securities, with prior biopharma equity research positions at several firms.

Kalaris Therapeutics names Liisa Bayko as CFO

Kalaris names new chief financial officer

Related News

Innovative Industrial Properties Inc <IIPR.N>: Piper Sandler raises target price to $51 from $45

Anixa Biosciences director Lewis H. Titterton Jr acquires 12,000 common shares valued at $41,640

Jasper Therapeutics director Patrick J. Crutcher files initial beneficial ownership statement

Kinder Morgan VP Michael P. Garthwaite disposes of $50,400 in common shares

Curbline Properties Corp. <CURB.N>: Piper Sandler Raises Target Price to $39 From $32